Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site
Hidetoshi Hayashi(Kindai University Sakai Hospital), Kazuhiko Nakagawa(Dana-Farber Cancer Institute), Kazuto Nishio(Kindai University), Yasutaka Chiba(Kindai University Hospital), Kazuko Sakai(Ochanomizu University), Yuichi Takiguchi(Chiba University), Yosuke Togashi(Okayama University), Shin Takahashi(Institute of Aging), Shuta Tomida(Okayama University), Hisateru Yasui(Kobe City Medical Center General Hospital), Yusuke Onozawa(Shizuoka Cancer Center), Koji Matsumoto(Hyogo Prefectural Cancer Center), Chihiro Kondoh(Toranomon Hospital), Toshiyuki Sawa(Gifu Municipal Hospital), Hironobu Minami(Kobe University), Hiroki Ueda(Wakayama Medical University), Yasuo Iwamoto(Hiroshima City Asa Citizens Hospital), Yoshihiko Segawa(Saitama Medical University), Kohei Akiyoshi(Osaka City General Hospital), Yoshihiko Fujita(Kindai University)
Cited by 119
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Reduced Expression of the <b> <i>let-7</i> </b> MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival
|Cancer Research|2004|2.4k